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Phosphorus (P) and calcium (Ca) are essential components of 
nutrition support therapy. Regulation and homeostasis of P and 
Ca in the body are closely interrelated, and typically they have 
an inverse relationship with respect to serum concentrations. 
Nutrition support clinicians must understand P and Ca homeo-
stasis to provide appropriate maintenance doses, to identify 
factors that may predispose patients to P and Ca disorders, to 
take measures to prevent disorders, and to promptly identify 
and correct disorders when they occur. This is particularly 
important in patients who are acutely ill or critically ill in the 
inpatient setting receiving parenteral nutrition (PN) and/or 
enteral nutrition (EN). This article will provide an overview of 
P and Ca for the nutrition support clinician, with some empha-
sis on the adult hospitalized inpatient.
P and Ca Homeostasis
Regulation of P and Ca is influenced primarily by serum P and 
ionized Ca concentrations ([P], [Ca]) and the actions of para-
thyroid hormone (PTH), vitamin D (1,25-dihydroxyvitamin 
D
3
), and calcitonin in the bones, kidneys, and intestines (Figure 
1).1-3 Increases in serum [P] can lead to a decrease in serum ion-
ized [Ca], and decreases in serum ionized [Ca] stimulate release 
of PTH. PTH increases P and Ca resorption/release from bone, 
increases Ca absorption and P excretion via the kidneys, stimu-
lates activation of vitamin D (1,25-dihydroxyvitamin D
3
, or cal-
citriol, the most active form) in the kidneys, and appears to 
increase absorption of P and Ca in the intestine.1-3 Vitamin D 
stimulates absorption of P and Ca from the intestine, stimulates 
P and Ca resorption/release from bone, and increases renal Ca 
resorption and increases urinary P excretion. Increases in serum 
ionized [Ca] and vitamin D concentrations will also suppress/
decrease PTH release, which will decrease activation of vitamin 
D. Increases in serum ionized [Ca] will stimulate release of cal-
citonin, which inhibits bone resorption and decreases serum 
ionized [Ca]. Magnesium may impair the synthesis and/or 
release of PTH, which can also affect Ca homeostasis.4
P and Ca Considerations for Patients 
Receiving Nutrition Support Therapy
Phosphorus
Phosphorus is an important intracellular anion, and phosphate 
(PO
4
) is one of the key forms of P in the body as relates to 
nutrition support therapy. PO
4
 is the primary form of P in the 
serum, and P ingestion in the diet and exogenous administra-
tion of P are also in the form of PO
4
. P serves many essential 
functions, including bone and cell membrane composition 
(e.g., phospholipids) as well as numerous metabolic processes. 
Phosphorus is a key component of 2 important molecules in the 
human body: adenosine triphosphate (ATP) and 2,3-diphos-
phoglycerate (2,3-DPG). Phosphorus (as PO
4
) provides 
565251 NCPXXX10.1177/0884533614565251Nutrition in Clinical PracticeKraft
research-article2014
From the 1Department of Clinical, Social and Administrative Sciences, 
University of Michigan College of Pharmacy, Ann Arbor, Michigan; and 
2Department of Pharmacy Services, University of Michigan Hospitals and 
Health Centers, Ann Arbor, Michigan.
Financial disclosure: None declared.
This article originally appeared online on December 30, 2014.
Corresponding Author:
Michael D. Kraft, PharmD, BCNSP, Department of Pharmacy Services, 
University of Michigan Health System, UH/B2 D314, SPC 5008, 1500 E. 
Medical Center Drive, Ann Arbor, MI 48109-5008, USA. 
Email: mdkraft@med.umich.edu
Phosphorus and Calcium: A Review for the Adult  
Nutrition Support Clinician
Michael D. Kraft, PharmD, BCNSP1,2
Abstract
Phosphorus (P) and calcium (Ca) serve vital roles in the human body and are essential components of nutrition support therapy. Regulation 
of P and regulation of Ca in the body are closely interrelated, and P and Ca homeostasis can be affected by several factors, including 
disease states, clinical condition, severity of illness, and medications. Nutrition support clinicians must understand these factors to prevent 
and treat P and Ca disorders in patients receiving nutrition support therapy. This review provides an overview of P and Ca for the adult 
nutrition support clinician, with some emphasis on the hospitalized inpatient. (Nutr Clin Pract. 2015;30:21-33)
Keywords
calcium; hypocalcemia; hypercalcemia; phosphorus; hypophosphatemia; hyperphosphatemia; nutritional support; parenteral nutrition; 
parenteral nutrition solutions
22 Nutrition in Clinical Practice 30(1)
energy-rich bonds in ATP, which is necessary for all physio-
logic and metabolic functions that require energy. 2,3-DPG is 
necessary for oxygen release from hemoglobin and delivery to 
tissues.5-11 These functions are especially important in criti-
cally ill patients who may experience hypermetabolism and 
may have higher oxygen requirements. Adequate total body P 
is also necessary for glucose use and glycolysis, protein syn-
thesis, neurological function, and muscle function (especially 
the myocardium and diaphragm).5-11
The normal serum P concentration ([P]) is about 2.7–4.5 
mg/dL (~0.9–1.45 mmol/L); however, approximately 1% of 
total body P is in the extracellular fluid, with the majority of P 
found in the bones and soft tissues.5-7 Therefore, serum [P] 
may not correlate with total body P. Although serum concentra-
tions of electrolytes are the most readily available monitoring 
parameter, it is important to make a complete assessment of the 
patient and consider factors that may affect serum levels and 
total body homeostasis of P (eg, severe malnutrition leading to 
depletion of total body P, chronic kidney disease (CKD) lead-
ing to decreased elimination of P, medications that can affect 
serum [P] and P homeostasis).
Given the numerous functions of P, especially the key role in 
ATP and 2,3-DPG, it is clear that P is an important component 
of nutrition support therapy. The Recommended Dietary 
Allowance for healthy adults is approximately 700 mg (~23 
mmol) per day.12 Most standard EN formulations contain 
approximately 700–1,200 mg (22–39 mmol) of P per liter of 
formula. Most unstressed, well-nourished adult patients with 
normal renal function receiving PN require approximately 20–
40 mmol/day,13 or approximately 10–15 mmol of P per 1,000 
kcal,8 to maintain normal serum [P]. Increasing total caloric 
load has been correlated with decreasing serum [P] in patients 
receiving PN.8 Severe hypophosphatemia and associated 
sequelae have been described in patients who did not receive 
appropriate phosphate supplementation with nutrition sup-
port.8,9 Patients who received PN without P supplementation 
developed severe hypophosphatemia and decreased erythrocyte 
ATP and 2,3-DPG with an associated increase in hemoglobin 
affinity for oxygen (suggesting decrease in oxygen delivery). In 
addition, hypophosphatemia led to changes in intermediates of 
glycolysis, suggesting a reduction in erythrocyte glycolysis.9 
There was also a significant correlation between total calories 
administered and the decrease in [P], as well as the amount of P 
administered and increase in serum [P].8
Severely malnourished patients will likely have higher daily 
P requirements when initiating nutrition support and should 
be supplemented accordingly to prevent hypophosphatemia 
associated with refeeding syndrome.14 Critically ill and trauma 
Figure 1. Calcium and phosphorus regulation in the human body.1-3 Ca, calcium; P, phosphorus; PTH, parathyroid hormone.
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patients with normal renal function may also require higher 
daily maintenance doses. Patients with thermal injury,15,16 
patients with traumatic brain injury,17,18 and those who have 
undergone liver resection19 also have increased P requirements. 
Patients with renal insufficiency will likely need P restriction, 
and serum [P] should be closely monitored as they are at risk for 
hyperphosphatemia.
Monitor serum [P] routinely (eg, daily) in well-nourished 
adult inpatients receiving nutrition support therapy. Monitor 
serum [P] more closely when initiating nutrition support in mal-
nourished patients (eg, every 8–12 hours for the first several 
days) as they have a higher risk of developing hypophosphate-
mia, refeeding syndrome, and subsequent complications includ-
ing seizures, coma, respiratory failure, and even death.9,14,20-23
Calcium
Calcium serves a key role in bone structure, blood coagulation, 
platelet adhesion, endocrine and exocrine secretory functions, 
neuromuscular activity, and electrophysiology of the heart and 
smooth muscles. The normal range for total serum [Ca] is 
approximately 8.6–10.2 mg/dL (~2.15–2.55 mmol/L). About 
99% of total body Ca is found in the bones, and <1% is found 
in the serum.2 Approximately 40%–50% of blood Ca is bound 
to plasma proteins, primarily albumin.2,24 Unbound or ionized 
Ca is the biologically active form of Ca and accounts for the 
other approximately 50% of Ca in the blood under normal con-
ditions.2 Ionized serum [Ca] is closely regulated by the endo-
crine system as described above, and this is a better indicator 
of the functional status of Ca metabolism than is total [Ca]. If 
available, measure the ionized [Ca] when monitoring Ca status 
in patients receiving nutrition support. The normal range for 
ionized serum [Ca] is approximately 1.12–1.30 mmol/L.
There is a poor correlation between ionized [Ca] and total 
[Ca] in some patient populations, in particular patients with 
acid-base disorders, patients with hypoalbuminemia, and criti-
cally ill patients.1,2,24-28 Metabolic acidosis decreases Ca bind-
ing to plasma proteins and will increase fraction of free or 
ionized serum Ca; conversely, metabolic alkalosis will increase 
Ca binding to plasma proteins and reduce the fraction of free/
ionized serum Ca.2,29,30
Hypoalbuminemia can cause a decrease in measured total 
serum [Ca], but there may be less of an impact on the free or 
ionized [Ca]. Therefore, clinicians may calculate a “corrected” 
serum [Ca] in patients with hypoalbuminemia or other condi-
tions that may affect total vs ionized [Ca]. The most common 
equation used in clinical practice to “correct” serum [Ca] due 
to hypoalbuminemia is the modified Orrell equation.25,31
Corrected serum Ca  mg / dL  = measured serum Ca  mg / dL[ ] ( ) [ ] ( ) + 
[0.8 (4-measured albumin(g / dL))]×
However, there are numerous other equations that have been 
used to correct serum [Ca], and as stated above, the corrected 
[Ca] may not correlate with ionized [Ca], especially in criti-
cally ill patients. Therefore, direct measurement of ionized 
[Ca] is recommended, especially in critically ill patients.25,26,32 
When ionized [Ca] is not available, it may be reasonable to 
calculate a corrected [Ca] in non–critically ill patients (ie, 
“floor” patients) using the equation above, as this is the main 
population in which the equation was developed.25,31 In criti-
cally ill patients, Dickerson et al28 found that 85% of patients 
with a total serum [Ca] <7 mg/dL had hypocalcemia (serum 
ionized [Ca] <1.12 mmol/L). When ionized [Ca] is not avail-
able in critically ill patients with a total serum [Ca] <7 mg/dL, 
these authors suggest immediately measuring a serum ionized 
[Ca] or provide conservative empiric treatment with intrave-
nous (IV) Ca and follow-up with a serum ionized [Ca] (refer to 
“Hypocalcemia” section below).28,33,34
The recommended adequate intake for Ca for healthy adults 
is approximately 1,000–1,200 mg (~50–60 mEq, or ~25–30 
mmol) per day, depending on gender and age.12 Most standard 
EN formulations contain approximately 700–1,200 mg (~17–
30 mmol) of Ca per liter of formula. Most adult patients with 
normal renal function will require a maintenance dose of 
approximately 10–15 mEq (~5–7.5 mmol) Ca per day with PN 
admixtures.13 There are no specific data or algorithms to guide 
adjustments in maintenance Ca doses for patients receiving PN 
or EN. When adjusting maintenance Ca doses, it is reasonable 
to adjust total daily doses by approximately 20%–50% depend-
ing on the daily dose, serum [Ca], responses to dose changes, 
and underlying clinical conditions.
Calcium absorption from the diet and oral supplements 
ranges from approximately 25%–35% depending on the 
source, salt form, and whether or not it is taken with food, and 
absorption is optimal from individual doses of ≤500 mg.12,35,36 
Calcium requires acid from the stomach to facilitate dissolu-
tion and absorption; therefore, patients receiving acid-suppres-
sion therapy or patients with achlorhydria may have reduced 
Ca absorption.35,37 Absorption of Ca from Ca citrate appears to 
be better than that of Ca carbonate, and Ca citrate is the pre-
ferred oral Ca supplement in patients receiving acid-suppres-
sion therapy or patients with achlorhydria.36,38,39
P and Ca Considerations in Specific 
Conditions
Patients receiving nutrition support therapy may have underly-
ing conditions that can affect P and Ca homeostasis through 
multiple mechanisms, and these patients will require special 
consideration. In all cases, treatment of the underlying 
condition(s) would be expected to reduce the impact on P and 
Ca. An in-depth discussion of all of these conditions is beyond 
the scope of this article, but they are mentioned briefly here, 
and the reader should refer to other excellent resources and 
reviews in the citations.
Patients with CKD may have multiple derangements in P 
and Ca homeostasis, including hyperphosphatemia, secondary 
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hyperparathyroidism, vitamin D deficiency, renal osteodystro-
phy, soft tissue calcification, and metabolic acidosis.40,41 
Patients with CKD will require monitoring of [Ca], [P], as well 
as PTH and vitamin D status. They may require P restriction 
and adjustments in Ca and vitamin D maintenance doses, as 
well as adjustment of chloride-acetate ratio to minimize risk of 
exacerbating metabolic acidosis and associated complications 
(if receiving PN).
Intestinal failure (IF) has a profound effect on patients and 
can result from several potential disease states. A proposed 
consensus definition describes IF as a result of “obstruction, 
dysmotility, surgical resection, congenital defect, or disease-
associated loss of absorption and is characterized by the 
inability to maintain protein-energy, fluid, electrolyte, or 
micronutrient balance.”42 IF can include patients with a variety 
of conditions that could predispose them to abnormalities in 
P and Ca homeostasis via several potential mechanisms, 
including (but not limited to) malabsorption, inflammatory 
bowel disease, and short bowel syndrome (SBS).42,43 These 
patients can have malabsorption of fat-soluble vitamins and 
can often develop vitamin D deficiency.44,45 Chronic steroid 
therapy (eg, for inflammatory bowel disease or other condi-
tions) can impair bone mineralization, decrease Ca absorption, 
and increase renal Ca excretion. Patients with IF or SBS may 
require supplemental Ca to prevent oxalate kidney stone for-
mation. These patients, especially those with IF or SBS, can 
also have large gastrointestinal (GI) fluid losses that can result 
in dehydration; in severe cases, this could lead to impaired kid-
ney function or acute kidney injury, potentially causing further 
acute P and Ca derangements. Large GI losses can also lead to 
magnesium deficiency, which can contribute to hypocalcemia. 
Patients with excessive GI losses of bicarbonate can also 
develop metabolic acidosis, which can affect vitamin D metab-
olism, bone buffering systems, and P and Ca homeostasis. 
Patients with these conditions will require monitoring for vita-
min D deficiency and may require increased maintenance 
doses of vitamin D and/or Ca, as well as adjustment of chlo-
ride-acetate ratio if receiving PN therapy.
Long-term PN therapy is associated with significant com-
plications, some of which can affect P and Ca homeostasis.46,47 
Patients with some of the diagnoses described above (eg, IF, 
SBS) can often require long-term PN therapy. Metabolic bone 
disease (MBD), including osteopenia, osteoporosis, and osteo-
malacia, is common in patients receiving long-term PN ther-
apy, and P and Ca homeostasis is an important aspect of 
MBD.47 This can be especially challenging because serum [P] 
and [Ca] can appear normal, so further patient evaluation is 
required (specifically related to P and Ca: serum intact PTH 
and 25-hydroxyvitamin D, 24-hour urine Ca and magnesium). 
Several factors can contribute to abnormalities in P and Ca 
homeostasis and MBD in patients receiving long-term PN, 
including malabsorption, increased renal Ca excretion, vitamin 
D deficiency, metabolic acidosis, aluminum accumulation/tox-
icity, decreased exposure to ultraviolet light (contributing to 
vitamin D deficiency), and lack of physical activity/weight-
bearing exercise.46,48 High protein doses can lead to calciuria 
that exceeds increases in glomerular filtration rate.49 In addi-
tion, shorter durations of total daily Ca infusion may reduce 
retention of the dose. Several steps should be taken to prevent 
MBD in patients receiving long-term PN therapy.46 Specifically 
with respect to P and Ca directly, this includes providing appro-
priate maintenance doses (initially 15 mEq/d of Ca and Ca:P 
ratio of approximately 1:2, both adjusted to serum concentra-
tions), along with an appropriate maintenance dose of vitamin 
D with the parenteral multivitamin preparation; encouraging 
weight-bearing exercises and appropriate exposure to ultravio-








 can combine to form dibasic calcium phos-
phate (CaHPO
4
) and precipitate out of solution if concentra-
tions exceed limits of compatibility.13 The U.S. Food and Drug 
Administration (FDA) published a safety alert in response to 2 
deaths associated with Ca-PO
4
 precipitation in PN.50 Autopsy 
reports revealed diffuse microvascular pulmonary emboli con-
taining Ca-PO
4
 precipitates. Despite this safety alert, other 
deaths have been reported due to pulmonary emboli from a 
precipitate containing Ca and PO
4
.51
Several factors can affect Ca-PO
4
 solubility in PN admix-
tures,13,50 including:
•• Final pH
•• Final amino acid concentration (which can have a sig-
nificant effect on final pH of the PN admixture, and PO
4
 
can bind with amino acids, reducing availability to bind 
with Ca)
•• Calcium salt (Ca gluconate is the preferred Ca salt in 
PN because it has a low dissociation constant and less 
free Ca available to bind PO
4
 in solution)
•• Order of mixing (Ca and PO
4
 salts should not be added 
simultaneously or consecutively when compounding 
PN admixtures)
•• Temperature (as temperature increases, more Ca and 
PO
4




•• Time (the longer Ca and PO
4
 are in solution, the higher 
the risk Ca-PO
4
 precipitation will occur)
Pharmacists must follow safe PN practices and verify 
Ca-PO
4
 compatibility when compounding all PN admixtures. 
When prescribing, compounding, and administering PN 
admixtures, clinicians should follow these guidelines13,50:
•• Verify compatibility of the prescribed amounts of Ca-PO
4
 




solubility curves; in addition to the above factors, Ca-PO
4
 
solubility curves and compatibility are also affected by 
the specific amino acid formulation, the concentration of 
other PN components, and the use of cysteine.
•• Consider the amount of PO
4
 from all sources (including 










 salts early in the compounding sequence, and 
then add Ca toward the end of the compounding 
sequence.
•• Consider the volume of the admixture at the time Ca is 
added when assessing Ca-PO4 compatibility (not neces-
sarily the final/total volume).50
•• Periodically agitate the PN admixture, and check for 
precipitation during compounding.
•• Use an appropriate filter when infusing the PN admix-
ture (1.2-µm filter for a total nutrient admixture, 0.22-
µm filter for a 2-in-1 PN admixture).
•• Monitor the patient for any evidence of adverse effects 
related to embolization of a precipitate.
•• Store PN admixtures at the appropriate temperature 
depending on the time between compounding and 
administering to the patient.
Treatment of P and Ca Abnormalities
Hypophosphatemia
Hypophosphatemia (serum [P] <2.7 mg/dL [~<0.9 mmol/L]) 
has been reported to occur in approximately 2%–3% of hospi-
talized patients but in as high as 28%–80% of critically ill 
patients (eg, trauma, sepsis, intensive care unit [ICU]), and it 
Table 1. Potential Causes of Hypophosphatemia in Adult Patients.5-7,52,53,60




Iatrogenic (inadequate phosphorus 
maintenance/supplementation)
Alcohol/alcoholism
Administration of carbohydrate loads, 
refeeding syndrome
Respiratory alkalosis











Antacids (eg, calcium-, magnesium- and 
aluminum-containing antacids)










Diuretics (eg, loop diuretics, thiazide 
diuretics, osmotic diuretics)





has been associated with severe adverse events.52,53 Several 
reports describe hypophosphatemia associated with the initia-
tion of nutrition support, including oral nutrition, EN, and 
PN.8,9,20-23,54-57 Severe hypophosphatemia (eg, serum P concen-
tration <1 mg/dL [~<0.3 mmol/L]) has been associated 
with impaired diaphragmatic contractility and acute 
respiratory failure, tissue hypoxia, decreased myocardial con-
tractility, paresthesias, weakness, confusion, disorientation, 
encephalopathy, areflexic paralysis, seizures, coma, and even 
death.5-11,20-23,54,55,57-59 Hypophosphatemia has also been asso-
ciated with higher mortality, longer duration of hospitalization, 
longer duration of mechanical ventilation, and other conse-
quences in some studies of various hospitalized adult patient 
populations.53 Acutely ill and critically ill adult patients often 
have underlying conditions that predispose them to developing 
hypophosphatemia and/or receive medications that can cause 
hypophosphatemia. Table 1 lists some potential causes of 
hypophosphatemia in adult patients.5-7,52,53,60 When administer-
ing carbohydrate loads (eg, with EN or PN), provide an ade-
quate maintenance dose of phosphate as described above to 
decrease the risk of hypophosphatemia, especially in malnour-
ished patients who are at risk for developing severe hypophos-
phatemia and refeeding syndrome.8,9,14,20-23 Severely 
malnourished patients (with normal renal function) at risk for 
refeeding syndrome may initially require 25%–50% higher 
doses of P to prevent hypophosphatemia when initiating nutri-
tion support.
Treatment of hypophosphatemia depends on the magnitude 
and whether the patient is symptomatic. In addition, under-
standing the underlying cause(s) of low serum [P] is important 
to guide treatment (eg, Is the low serum [P] due to inadequate 
maintenance doses, inadequate absorption, intracellular shifts, 
increased elimination, or a combination of these factors? Is this 
a true P deficiency?). Correct/remove the underlying cause 
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when feasible (eg, medication-induced hypophosphatemia). 
Asymptomatic mild hypophosphatemia may be treated with 
oral P supplementation if the GI tract is functional; however, 
oral P supplements can cause diarrhea, and oral absorption 
may be variable. Patients with symptomatic, moderate-severe 
hypophosphatemia and patients who cannot tolerate oral sup-
plements should receive IV P supplementation to correct serum 
[P]. Estimating the appropriate dose of P is largely empiric 
because serum concentrations may not correlate with total 
body stores. A few different regimens based on patient weight 
and serum [P] have now been published, but these have been 
primarily in critically ill trauma patients and surgical ICU 
patients with normal renal function.61-63 There are several other 
published reports of fixed-dose phosphate supplementation in 
patients with normal renal function.64-70 Based on these pub-
lished reports, Table 2 provides one approach to IV P dosing 
for treating hypophosphatemia in patients with normal renal 
function.14,61-70 Although there are no specific data or algo-
rithms to guide P repletion in patients with impaired renal 
function receiving nutrition support who are not being treated 
with continuous renal replacement therapy (CRRT), consider 
administering ≤ 50% of the initial empiric P dose initially. 
Patients being treated with CRRT may require higher initial 
doses (ie, closer to empiric doses used for patients with normal 
renal function), depending on the severity of hypophosphate-
mia, the amount of P being removed with CRRT, and whether 
P is used in the dialysate/replacement fluid.
Oral P supplementation may be considered in patients with 
mild, asymptomatic hypophosphatemia receiving oral nutri-
tion or EN (Table 3). A liquid form of oral P would be preferred 
in patients receiving EN (eg, powder for reconstitution, crush-
ing oral tablets and dissolving in purified water). If liquid 
Table 2. Suggested Intravenous Treatment of  
Hypophosphatemia.a,14,61-70












<1.5 mg/dL (~<0.5 mmol/L) (severe 
symptomatic hypophosphatemia)
0.32–0.64 mmol/kgc
aNormal renal function; for patients with decreased creatinine clearance 
(eg, <50 mL/min), consider giving ≤50% of the initial empiric dose. 
Maximum recommended infusion rate = 7–7.5 mmol phosphate/h.
bConsider using adjusted body weight (AdjBW) in patients who are 
significantly obese (weight >130% of ideal body weight (IBW) or body 
mass index ≥30 kg/m2): AdjBW (males) = ([wt (kg) – IBW (kg)] × 0.3) + 
IBW; AdjBW (females) = ([wt (kg) – IBW (kg)] × 0.25) + IBW.
cDoses up to 1 mmol/kg have been reported in critically ill adult trauma 
patients.
supplements are administered via an enteral tube, EN should 
be held before and after administration, the powder for recon-
stitution would be preferred over crushing oral tablets and dis-
solving in water, the medication should be diluted prior to 
administration (purified water or saline) and should not be 
coadministered with any other medications or products, and 
the tube should be flushed with at least 15 mL of purified/ster-
ile water before and after administration.71 Although institu-
tions may include an option for enteral P supplementation as 
part of an electrolyte correction protocol or guideline, there are 
limited published data describing the efficacy of this approach, 
especially in critically ill patients. Oral P supplementation may 
be limited by the volume required for dilution, diarrhea (espe-
cially with higher doses), and multiple interruptions of EN. In 
addition, oral P absorption may be decreased in patients with 
vitamin D deficiency.5,72 Some have added P supplements 
directly to EN formulas (either oral or IV dosage formula-
tions),56,62 and this approach may be efficacious when treating 
asymptomatic hypophosphatemia,56 although recent guidelines 
do not recommend this practice.71 One report of 2 malnour-
ished patients demonstrated enteral P contained in EN formu-
lations was not adequate to prevent hypophosphatemia and 
ultimately required IV supplementation to correct serum [P], 
although there may have also been other contributing factors in 
these cases.72
Patients with persistent hypophosphatemia may require a 
daily P supplement. Patients who cannot receive oral supple-
ments, critically ill patients, and/or those with moderate-severe 
hypophosphatemia may require IV supplementation and/or 
increased maintenance P doses in PN admixtures. There are no 
specific data to guide adjustments of P maintenance dosing in 
PN prescriptions, but a reasonable approach is to adjust main-
tenance doses of P by approximately 10%–25% as needed to 
avoid or reverse P deficits and to monitor serum [P] for 
response. Further adjustments to P maintenance dosing, P sup-
plementation, and correction of hypophosphatemia should be 
guided by clinical response to doses and changes in serum [P] 
and clinical condition in all patients.
The IV P preparations used are available as the potassium 
(K) or sodium (Na) salts. Potassium phosphate (KPhos) can be 
used in patients with simultaneous hypokalemia; otherwise, 
sodium phosphate (NaPhos) is recommended. Clinicians must 
also take into consideration the K and Na content of all P prep-
arations (IV and oral); 1 mmol of IV KPhos contains approxi-
mately 1.47 mEq of K, and 1 mmol of IV NaPhos contains 
approximately 1.33 mEq of Na.
IV P doses are typically infused over 4–6 hours (depending 
on the dose) to reduce the risk of Ca-PO
4
 precipitation and min-
imize infusion-related adverse effects (eg, thrombophlebitis 
from KPhos). Doses can be infused up to a rate of approxi-
mately 7–7.5 mmol P per hour.61,62,69 A few reports have dem-
onstrated safe administration of P doses up to 15 mmol/h.70,73 
However, one study failed to demonstrate a difference in serum 
[P] between the slower (7.5 mmol/h) and faster (15 mmol/h) 
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Table 3. Select Oral Sodium/Potassium Phosphate Dosage Forms.a
Product Dosage Form (Dose) Phosphate Content Sodium Content Potassium Content
Phos-NaK Powder for solution (1 packet) 250 mg (8 mmol) 160 mg (6.9 mmol) 280 mg (7.1 mmol)
K-Phos Neutral or
Phospha 250 Neutral
Tablet (250 mg) 250 mg (8 mmol) 298 mg (13 mmol) 45 mg (1.1 mmol)
K-Phos No.2 Tablet (250 mg) 250 mg (8 mmol) 134 mg (5.8 mmol) 88 mg (2.3 mmol)
aPhosphorus 31 mg = 1 mmol; sodium 23 mg = 1 mmol (1 mEq); potassium 39 mg = 1 mmol (1 mEq).
groups at the end of infusion or 24 hours after infusion, more 
patients in the faster infusion groups developed hyperkalemia, 
and there was a trend toward increased fractional excretion of 
PO
4
 in the faster infusion groups (suggesting the faster infusion 
rate may exceed the renal threshold for reabsorption).70 
Carefully evaluate risk/benefit when considering increased 
infusion rates of IV P (eg, severity of hypophosphatemia and 
symptoms, risk of hypocalcemia and Ca-PO
4
 precipitation, rate 
of K infusion [if using KPhos], risk of hyperkalemia, and poten-
tial adverse effects). KPhos may require administration via a 
central vein due to irritation or phlebitis with peripheral IV 
administration (depending on the total dose, final K concentra-
tion, and the rate of K infusion); one study infused doses of ≥30 
mmol of KPhos in 250 mL of 5% dextrose via a central venous 
catheter.63 Use caution when treating hypophosphatemia with 
IV P in patients with elevated serum total Ca/ionized Ca levels 
to avoid Ca-PO
4
 precipitation and hypocalcemia.
Phosphorus can shift quickly between body compartments, 
and serum concentrations can fluctuate.7,64 Some publications, 
guidelines, and protocols describe assessing a serum [P] at the 
end of supplementation or within 2–6 hours after completing a 
dose69,70,73; however, data are lacking on the optimal time to 
recheck serum [P] after supplementation. Several published 
studies on the treatment of hypophosphatemia describe monitor-
ing serum [P] within approximately 12–24 hours after supple-
mentation or on a daily basis.61-63,65,69 Despite this, it may be 
prudent to monitor serum [P] more frequently in some patients 
with severe hypophosphatemia until serum concentrations nor-
malize. Administer additional P supplements until the patient is 
asymptomatic and the serum [P] is at least >2.0 mg/dL; the goal 
is to return the serum [P] to the normal range (ie, 2.7–4.5 mg/dL) 
and avoid symptoms. Some patients will require multiple doses 
over several days to completely correct hypophosphatemia, 
especially those with severe malnutrition/refeeding syndrome, 
those with P depletion, and critically ill patients.57,61,62,65,70,74
Finally, when using weight-based dosing, there are no 
definitive data or recommendations for “adjusting” weight in 
obese patients or what threshold should be used to adjust 
weight (eg, using a percentage above ideal body weight [IBW] 
or based on body mass index). Total body water is slightly 
higher in males than in females, and adipose tissue is com-
posed of approximately 10%–30% water.75-79 Often in practice, 
an adjustment of 25%–40% of the IBW is added to the IBW to 
determine the adjusted body weight (AdjBW) or dosing 
weight, and this depends on whether the adjustment is related 
to dosing nutrition, electrolytes, or medications (as well as the 
properties of the medication). To minimize the risk of overdos-
ing, consider using an AdjBW in obese patents (weight >130% 
of IBW or body mass index ≥30 kg/m2) when using weight-
based dosing of electrolytes:
AdjBW males  = wt kg   IBW kg  x 0.3  + IBW( ) ( ) ( ) ( )−
AdjBW females  = wt kg   IBW kg  x 0.25  + IBW( ) ( ) ( ) ( )−
Hyperphosphatemia
Hyperphosphatemia is defined as a serum [P] >4.5 mg/dL 
(~>1.45 mmol/L). The most common cause of hyperphospha-
temia, especially in hospitalized and critically ill patients, is 
impaired renal function.4,5 Excessive IV and/or oral adminis-
tration of P can also cause hyperphosphatemia and would be 
more likely in patients with renal insufficiency.4,5,80-82 Other 
causes of hyperphosphatemia can include immobility, hemoly-
sis, rhabdomyolysis, and tumor lysis.4 Severe hyperphosphate-
mia, acute kidney injury, and dehydration have been reported 
following oral and rectal administration of P-containing laxa-
tives (for treatment of constipation or as a bowel preparation), 
particularly in patients with compromised renal function.80-84 
Several over-the-counter products were voluntarily discontin-
ued in 2008,83 although an oral solution and an enema are again 
available (over-the-counter products). A prescription product is 
also available but carries a boxed warning and a Risk Evaluation 
and Mitigation Strategy as required by the U.S. FDA.83 Other 
potential causes of hyperphosphatemia include hypoparathy-
roidism, vitamin D intoxication, bisphosphonates, acidosis 
(metabolic, respiratory), hemolysis, rhabdomyolysis, and 
tumor lysis syndrome.4,5
Hyperphosphatemia can lead to hypocalcemia due to 
Ca-PO
4
 precipitation, which can further lead to clinical mani-
festations of hypocalcemia such as tetany.4,5 Furthermore, 
Ca-PO
4
 crystals can also deposit into soft tissues and cause 
further organ damage, especially in the lungs, myocardium, 
and blood vessels.4,5,40,85,86 The risk of Ca-PO
4
 precipitation 
appears to increase when the serum Ca × P is >55–60 mg2/dL2, 
and this product should be maintained <55 mg2/dL2.40,85,87 
However, more recent guidelines suggest the Ca × P product 
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may have limited utility in clinical practice, and individual 
serum levels should be evaluated to guide a treatment plan.40
Treatment of hyperphosphatemia requires a complete 
assessment of the patient, including laboratory values, signs/
symptoms, and clinical condition. Although serum [P] may not 
indicate total body P, this is the most readily available monitor-
ing parameter. Identify and correct the underlying cause when 
possible. Adjust/restrict the daily P intake (eg, reduce daily 
doses in the PN prescription; consider using a renal EN for-
mula) in patients with impaired renal function and hyperphos-
phatemia. Patients receiving various forms of renal replacement 
therapy, including CRRT, peritoneal dialysis, or intermittent 
hemodialysis, will have differing requirements because of the 
variation in P removal with each of these therapies. Oral P 
binders, available as Ca, aluminum, and magnesium salts, as 
the non-ionic P binder sevelamer, and the newer ionic agent 
lanthanum carbonate that was recently approved by the U.S. 
FDA, are effective in lowering serum [P], but most data are in 
patients with CKD.88,89 Table 4 lists potential pharmacologic 
treatments of hyperphosphatemia.40,41,88,89
Use ion-containing P binders cautiously, especially those 
containing magnesium and aluminum. Aluminum can cause 
constipation, magnesium can cause diarrhea, and both can 
accumulate in patients with impaired renal function and lead to 
toxicity. Lanthanum carbonate has been associated with nau-
sea, vomiting, abdominal pain, diarrhea, and constipation.89 
Calcium salts and non-ionic P binders are preferred in patients 
with CKD or when long-term therapy is required; lanthanum 
carbonate was recently approved by the U.S. FDA and may 
also be an option.40,41,88,89 Calcium-containing P binders should 
be avoided in patients with hypercalcemia or evidence of calci-
fication. Continued use of P binders may paradoxically result 
in hypophosphatemia.
Because of the delayed onset of therapies for hyperphos-
phatemia, frequent monitoring of serum [P] is likely not 
needed in most patients. Routine monitoring of serum [P] (eg, 
every 24–48 hours) is probably appropriate for most adult 
hospitalized patients; patients who are critically ill, patients 
with severe symptoms, and/or those receiving CRRT may 
require more frequent monitoring. The goals of therapy should 
include returning the serum [P] to normal (eg, 2.7–4.5 mg/dL 
[~0.9–1.45 mmol/L]), avoiding or resolving symptoms of 
hyperphosphatemia, and possibly maintaining the serum Ca-P 
product <55 mg2/dL2.40,85,86
Hypocalcemia
Hypocalcemia (total serum [Ca] <8.6 mg/dL [~2.15 mmol/L], 
ionized [Ca] <1.1 mmol/L) has been reported in approximately 
15%–88% of hospitalized adult patients,90 and one study 
observed hypocalcemia in approximately 21% of critically ill 
trauma patients.25 Hypocalcemia is often associated with hypo-
albuminemia in hospitalized patients, but other causes can 
include sepsis, pancreatitis, renal insufficiency, hypoparathy-
roidism, administration of blood preserved with citrate, hypo-
magnesaemia, and hyperphosphatemia.2,24 Magnesium 
deficiency may impair PTH release and/or activity and contrib-
ute to hypocalcemia.4,90-92
The hallmark sign of severe acute hypocalcemia is tetany, 
but other neuromuscular, cardiovascular, and central nervous 
Table 4. Pharmacologic Treatment of Hyperphosphatemia.40,41,88,89
Medication Dosage Forms Initial Recommended Dosea Maximum Recommended Dosea
Calcium acetate Tablet: 667 mg
Gelcap: 667 mg
1,334 mg 3 times daily with 
meals
4 tablets with meals; avoid 
hypercalcemia
Calcium carbonate Tablet, capsule, liquid, and 
powder; various strengths
1–2 g 3 times daily with meals 7 g/d; avoid hypercalcemia
Magnesium hydroxide Tablet: 300 mg, 600 mg
Liquid: 400 mg/5 mL, 800 
mg/5 mL
1–2 tablets 3 times daily with 
meals
or
5–15 mL 3 times daily with 
meals
2–4 tablets 4 times daily with 
meals
or
15 mL 4 times daily with meals 
and at bedtime
Aluminum hydroxide Tablet: 300 mg, 600 mg
Suspension: 320 mg/5 mL
1–2 tablets, or 15–30 mL
or
3–4 times daily, with meals 
and at bedtime
1,800 mg (3–6 tablets) every 4 
hours
or




Tablet: 400 mg, 800 mg
Packet (powder for oral 
suspension): 0.8 g, 2.4 g
800–1,600 mg 3 times daily 
with meals
4,000 mg 3 times daily with 
meals
Lanthanum carbonate Chewable tablet: 500 mg, 
750 mg, 1000 mg
500 mg 3 times daily with 
meals
4,500 mg daily in divided doses
aMay require higher doses in rare situations or in some patients with chronic renal insufficiency and severe hyperphosphatemia; the dose should be 
titrated to achieve the goal serum phosphorus (P) level in these situations. Calcium 40 mg = 1 mmol (2 mEq).
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Table 5. Suggested Empiric Dosing of Intravenous Ca.1,2,28,32-34,90,103
Degree of Hypocalcemia Preferred Ca Salta Suggested IV Doseb
Mild-moderate, asymptomatic
Serum ionized [Ca] ~1–1.12 mmol/L
Gluconate 1–2 g Ca gluconate, infused over 1–2 h (1 g Ca 
gluconate/h)
Severe
Serum ionized [Ca] <1 mmol/L
Gluconate 3–4 g Ca gluconate, infused over 3–4 h (1 g Ca 
gluconate/h)
Severe, symptomatic hypocalcemia 
(with serum ionized [Ca] <1 mmol/L)
Gluconate or 
chloride
1–3 g Ca gluconate, or 500–1,000 mg Ca chloride, infused 
over 10 min, may repeat ~ every 60 min as needed until 
stabilized, then supplement as suggested above based on 
serum ionized [Ca] and patient symptoms/ clinical status
Ca, calcium.
aCalcium chloride should be administered via a central venous catheter to avoid extravasation and tissue necrosis; 1,000 mg Ca chloride = 13.6 mEq Ca; 
1 g Ca gluconate = 4.56 mEq Ca.
bTypically, a Ca gluconate dose of 1–2 g (4.56–9.12 mEq Ca) is mixed in 100 mL of D5W or NS and infused at a maximum rate of 1 g/h for routine 
supplementation (nonemergent situations).
system symptoms can be present with mild-moderate hypocal-
cemia. Symptoms can include muscle cramps, paresthesias, 
seizures, prolonged QT interval, heart block, and ventricular 
fibrillation.1,2 Chronic hypocalcemia can lead to dermatologic 
manifestations including dermatitis, eczema, brittle grooved 
nails, and hair loss.1
Treatment of hypocalcemia should include treating or remov-
ing the underlying cause when feasible. IV Ca gluconate and Ca 
chloride are used to treat patients with severe hypocalcemia, 
patients with severe symptoms due to hypocalcemia, or when 
rapid correction of serum [Ca] is required. Calcium chloride pro-
vides 3 times more elemental Ca than does an equivalent amount 
of Ca gluconate, and there have been dosing errors reported due 
to confusion about the Ca salt, Ca dose, and the way Ca was 
ordered.93-96 It would be prudent to establish a standardized 
method for ordering Ca supplementation to minimize the risk of 
errors.97-99 This approach should include using Ca gluconate as 
the preferred salt for routine Ca maintenance dosing and supple-
mentation and restricting Ca chloride for use in urgent and emer-
gent situations. Calcium gluconate is the preferred salt for 
peripheral venous administration as Ca chloride can cause tissue 
necrosis if it extravasates into surrounding tissues.100,101
When prescribing Ca maintenance doses or supplemental 
doses, the order should contain the dose of Ca, the Ca salt, and 
the dose either in grams, milligrams, or milliequivalents; avoid 
dosing using the terms amp, ampoule, and milliliter.97 Calcium 
should not be infused in the same IV line as solutions contain-
ing P due to risk of Ca-PO
4
 precipitation.
Treatment of asymptomatic hypocalcemia due to hypoalbu-
minemia is not indicated. Given the discussion regarding “cor-
recting” serum [Ca] in patients with hypoalbuminemia, it is 
preferred to monitor ionized [Ca], especially in critically ill 
patients.25,26,28 There is also debate over the benefit or need to 
correct asymptomatic hypocalcemia; however, given the 
essential physiologic functions of Ca and the potentially detri-
mental effects of severe hypocalcemia, many clinicians decide 
to treat hypocalcemia to avoid severe hypocalcemia and 
potentially negative consequences, especially in critically ill 
patients.34,102 Table 5 describes suggested empiric intermittent 
IV Ca replacement doses based on the severity of hypocalce-
mia in adult patients.1,2,28,32-34,90,103 Fixed doses, rather than 
weight-based doses, are recommended for empiric therapy 
based on recent data in critically ill patients that did not dem-
onstrate a significant correlation between Ca dose normalized 
for weight and serum ionized [Ca] response.33,34 As discussed 
above, when ionized [Ca] is not available in critically ill 
patients with a total serum [Ca] <7 mg/dL and without symp-
toms of hypocalcemia, consider immediately measuring a 
serum ionized [Ca] or provide conservative empiric treatment 
with IV Ca (eg, 1–2 g Ca gluconate, see Table 5) and follow up 
with a serum ionized [Ca].28,33,34
Infuse intermittent doses at a maximum rate of 1 g Ca 
gluconate/h (~4.56 mEq elemental Ca/h), as this may improve 
Ca retention and may be a safer approach.32-34 Subsequent 
doses should be based on the patient’s response to therapy and 
clinical condition. In critically ill patients, it may take approxi-
mately 10 hours for serum [Ca] to stabilize after a dose (eg, 4 
g Ca gluconate infused over 4 hours), possibly sooner for lower 
doses,32 so it is reasonable to recheck serum/ionized [Ca] 
approximately 10–12 hours after a supplement (if the patient is 
not symptomatic due to hypocalcemia). IV Ca doses can be 
repeated as needed until serum/ionized [Ca] is normalized, and 
it may take several doses to completely correct [Ca] in some 
patients.32-34
Severe, symptomatic hypocalcemia must be corrected 
promptly with IV Ca++ administration (Table 5).1,2,28,32-34,90,103 
To control severe symptoms (eg, tetany, seizures, cardiac man-
ifestations), treat with an initial dose of Ca chloride 500–1,000 
mg (6.8–13.6 mEq Ca, if the patient has central IV access) or 
Ca gluconate 1–3 g (4.56–13.7 mEq Ca) over 10 minutes.2,90,103 
In some cases, doses may need to be repeated as often as 
approximately every 60 minutes, and in rare cases, more 
aggressive dosing has been suggested (eg, beta-blocker over-
dose, cardiac arrest).2,90,103 However, discussion of emergency 
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situations is beyond the scope of this article. Calcium chloride 
should always be infused via a central vein to avoid extravasa-
tion and tissue necrosis.100,101
Oral Ca supplements may be considered in patients with 
mild-moderate hypocalcemia who are receiving EN or can tol-
erate oral medications, but this approach may not be feasible or 
adequate in critically ill patients. Table 6 describes the avail-
able Ca supplements, their elemental Ca content, and the avail-
able forms for specific administration routes. Some patients 
may require evaluation of PTH and vitamin D status (eg, 
patients with CKD or chronic hypocalcemia).
Patients may require adjustment of daily Ca maintenance 
doses in PN formulations or daily supplemental doses of oral 
Ca if receiving EN, depending on the patient’s clinical condi-
tion and the underlying cause of hypocalcemia. If present, cor-
rect concomitant hypomagnesaemia using magnesium 
supplements. When not actively treating severe hypocalcemia, 
monitor serum/ionized [Ca] every 24–48 hours initially in 
adult inpatients receiving nutrition support therapy.
Hypercalcemia
Hypercalcemia (total serum [Ca] >10.2 mg/dL [~2.55 
mmol/L], ionized [Ca] >1.3 mmol/L) can be characterized as 
mild-moderate hypercalcemia (total serum [Ca] = 10.3–12.9 
mg/dL [~2.6–3.2 mmol/L], ionized [Ca] ~1.3–1.6 mmol/L) or 
severe hypercalcemia (total serum [Ca++] ≥13 mg/dL [~≥3.25 
mmol/L], ionized [Ca] ≥1.6 mmol/L). The most common 
causes of hypercalcemia include malignancy and primary 
hyperparathyroidism.2,90,104 Other causes include vitamin A 
toxicity, vitamin D toxicity, milk-alkali syndrome, adrenal 
insufficiency, immobilization, Paget’s disease, rhabdomyoly-
sis, and medications (eg, thiazide diuretics, lithium).2,90,104,105 
Chronic hypercalcemia may cause Ca-PO
4
 precipitation, met-
astatic calcification, and renal failure.105 Patients with severe 
hypercalcemia can present with anorexia, fatigue, confusion, 
or cardiac manifestations including bradycardia or arrhyth-
mias with electrocardiograph changes.90,106,107 Severe hyper-
calcemia/hypercalcemic crisis requires immediate treatment 
because it can lead to acute kidney injury, ventricular arrhyth-
mias, obtundation, coma, and death.2,90,104
Treatment of hypercalcemia should include treating/remov-
ing the underlying cause when possible. Patients receiving PN 
may require temporary reduction or removal of Ca from their 
PN prescription, depending on the underlying cause and sever-
ity of hypercalcemia. Mild hypercalcemia does not require 
immediate treatment and typically responds to hydration and 
ambulation. Treatment of severe hypercalcemia/hypercalcemic 
crisis should begin immediately with IV hydration ± calcitonin 
and possibly addition of an IV loop diuretic (eg, furosemide) 
after the patient has received adequate fluid resuscita-
tion.104,105,107,108 Hemodialysis with low-Ca or Ca-free dialy-
sate may be necessary in life-threatening hypercalcemia, in 
patients with impaired renal function, and in patients with heart 
failure and/or volume overload.2,90,107,108
Administer hydration with isotonic IV fluid (initially more 
aggressive, eg, IV normal saline at a rate of ~200–300 mL/h) to 
reverse the volume contraction caused by hypercalcemia and 
facilitate Ca elimination.2,90,107 After adequately rehydrating 
the patient, IV loop diuretics may be considered to enhance 
renal Ca elimination and avoid fluid overload from saline 
hydration; however, rigorous data evaluating the efficacy of 
loop diuretics in this setting are lacking, and some do not rec-
ommend this therapy.90,107 If loop diuretics are used, ensure the 
patient has first received adequate fluid resuscitation, and 
monitor closely to avoid further volume depletion.107
Calcitonin inhibits bone resorption and increases renal Ca 
elimination, and it can be used in addition to IV hydration for 
treatment of acute hypercalcemia/hypercalcemic crisis. An ini-
tial dose of 4 units/kg given via the subcutaneous or intramus-
cular route every 12 hours will begin to reduce serum [Ca] 
within a few hours.107,109 The dose can be increased up to 6–8 
units/kg every 6 hours if the response is not adequate, but effi-
cacy of calcitonin appears to be limited to a few days due to the 
development of tolerance.107,109
Bisphosphonates (eg, pamidronate, zoledronic acid, etidro-
nate) are potent inhibitors of bone resorption, are often used in 
the treatment of hypercalcemia of malignancy,107 and have 
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been used in patients with chronic critical illness who have 
accelerated bone breakdown and associated MBD.110 
Pamidronate is given as a single IV dose of 60–90 mg infused 
over 2–24 hours. In patients with chronic critical illness who 
have accelerated bone breakdown, they may receive pamidro-
nate 30 mg IV daily × 3 days (along with calcitriol).110 
Zoledronic acid is given as a single IV dose of 4–8 mg infused 
over 15 minutes. Etidronate may be effective when given at a 
dose of 7.5 mg/kg/d IV over 2 hours for 3–7 days. 
Bisphosphonates may be given at the initiation of treatment, 
but they have a prolonged time to onset and longer duration of 
action. Serum [Ca] typically starts to decline within 1–2 days 
of the first dose, and the effect may persist for several weeks.107
Bisphosphonates are commonly used for the treatment of 
hypercalcemia of malignancy outside of the acute setting. 
Other medications including glucocorticoids, calcitonin, mith-
ramycin, and gallium nitrate have also been used.2,104,107,108
Monitor serum/ionized [Ca] more frequently during active 
treatment of severe hypercalcemia (eg, every 4–8 hours) and 
every 24–48 hours once hypocalcemia has been corrected.
Summary
Phosphorus and Ca are vital components of nutrition support 
therapy. There are many important physiologic, pharmaceuti-
cal, and clinical factors that can affect P and Ca homeostasis. In 
addition, there are important safety considerations for P and 
Ca, both when prescribing and compounding nutrition support 
therapy admixtures and when treating P and Ca abnormalities 
in patients. Clinicians must understand these factors to opti-
mize nutrition support therapy and avoid or minimize P and Ca 
derangements.
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